Lundbeck seeks regulatory advice after desmoteplase PhIII flop
This article was originally published in Scrip
Executive Summary
Lundbeck reported on 27 June that its Phase III DIAS-3 trial of desmoteplase, a fibrin-dependent plasminogen activator, failed to meet its primary endpoint in patients with acute ischemic stroke treated in the 3-9 hours time-window after onset.